We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Failure of Tumor Suppressor Gene Promotes Lung Cancer Development

By LabMedica International staff writers
Posted on 15 Dec 2008
A team of British and American cancer researchers has identified a tumor suppressor gene (TSG) that fails to function in both small and non-small cell lung cancers.

Investigators at the University of Nottingham (United Kingdom) and at the Washington University School of Medicine (St. More...
Louis, MO, USA) recently published two papers characterizing a gene that functions in normal lung tissue but is down regulated in lung tumors. The gene, known as LIM domain containing protein 1 (LIMD1), is located on chromosome 3p21.3.

In the first study, published in the November 15, 2008, edition of the International Journal of Cancer, the investigators used an anti-LIMD1 specific monoclonal antibody to investigate expression/localizations of the LIMD1 protein in a well-characterized tissue microarray of breast cancers and normal adjacent epithelial tissue. Results showed that LIMD1 expression was much higher in normal tissue. The location of LIMD1 activity was also found to be important. Nuclear LIMD1 activity was associated with normal tissue and less aggressive tumors, while cytoplasmic LIMD1 activity was linked to aggressive tumors.

The second paper, published in the December 5, 2008, online edition of the Proceedings of the [U.S.] National Academy of Sciences (PNAS), confirmed that LIMD1 was a bona fide TSG. Mice that were genetically engineered to lack LIMD1 were found to be predisposed to chemical-induced lung adenocarcinoma. Genetic inactivation of LIMD1 in mice heterozygous for the oncogenic K-RasG12D gene markedly increased tumor initiation, promotion, and mortality.

These studies, which were supported by a grant from the British Lung Foundation, may lead to possible new treatments and early screening techniques for lung cancer.

Related Links:
University of Nottingham
Washington University School of Medicine



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.